Ted C. Nark

CIK: 0001316851

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)2 (40.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AMRX

Amneal Pharmaceuticals, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

AMRX
Amneal Pharmaceuticals, Inc.
May 7, 2026
Exercise(M)
Direct
34.8K shares-
AMRX
Amneal Pharmaceuticals, Inc.
May 6, 2026
Award(A)
Restricted Stock Units
Direct
19.8K shares-
AMRX
Amneal Pharmaceuticals, Inc.
Nov 17, 2025
Sale(S)
Direct
50K shares at avg. $11.72$586K
AMRX
Amneal Pharmaceuticals, Inc.
May 6, 2025
Award(A)
Restricted Stock Units
Direct
34.8K shares-
AMRX
Amneal Pharmaceuticals, Inc.
May 5, 2025
Exercise(M)
Direct
40.3K shares-

		Type	Shares	Price		Ownership
May 7, 2026	AMRX Amneal Pharmaceuticals, Inc.	Exercise(M)	34,819	-	$0	Direct
May 6, 2026	AMRX Amneal Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	19,824	-	-	Direct
Nov 17, 2025	AMRX Amneal Pharmaceuticals, Inc.	Sale(S)	50,000	$11.72	$586,000	Direct
May 6, 2025	AMRX Amneal Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	34,819	-	-	Direct
May 5, 2025	AMRX Amneal Pharmaceuticals, Inc.	Exercise(M)	40,258	-	-	Direct

1-5 of 5 transactions

About Nark Ted C

Nark Ted C (SEC CIK 0001316851) files insider reports with the SEC as Director of Amneal Pharmaceuticals, Inc. (AMRX).

Signal8 holds 3 ownership filings by Nark Ted C, all Form 4s, filed between May 8, 2025 and May 8, 2026. Those filings report 5 transactions, from May 5, 2025 to May 7, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Nark Ted C's filings is in BRIDGEWATER, NJ.

Recent filings by Nark Ted C

May 7, 2026: Option exercise of AMRX shares (Form 4, code M).
May 6, 2026: Grant or award of AMRX derivative securities (Form 4, code A).
Nov 17, 2025: Open-market sale of AMRX shares (Form 4, code S).
May 6, 2025: Grant or award of AMRX derivative securities (Form 4, code A).
May 5, 2025: Option exercise of AMRX shares (Form 4, code M).

Other insiders filing for Amneal Pharmaceuticals, Inc. (AMRX)

BUCHI J KEVIN, Director
BOYER ANDREW S, Executive Vice President
Kiely John, Director
Shah Nikita, Executive Vice President
Daly Jason B., EVP, Chief Legal Officer
Patel Tushar Bhikhubhai, 10% Owner

How to read Form 4 transaction codes